Intriguingly, NF-κB activation was found to inhibit β-catenin/TCF activity through upregulation of LZTS2 in colon, liver, and breast cancer cells (Figure 2) but downregulate LZTS2 in glioma cells to promote β-catenin/TCF activity, strongly indicating a cell type-specific effect (69). The gene discussed is NFKB1; the disease is central nervous system cancer.